Fabien is a neuropharmacologist who cumulates more than 5 years of experience in the field of neurosciences and drug development (INSERM, Maastricht University, Servier). In particular, he has been working on the implication of BDNF/TrkB signaling in the pathophysiology and treatment of CNS disorders, and is co-author of 10 peer-reviewed articles in international scientific journals.
During the past 5 years, Fabien has held several positions in business development and entrepreneurship. He has worked as business developer at Brightlands (The Netherlands), where he was responsible for licensing IP from University and developing new start-ups in the field of biotechnology. He founded Axonova in 2017 and is the CEO of the company.
Fabien holds a joint European PhD degree in Neuropharmacology from Paris-Descartes University and Maastricht University, as well as a MBA degree in Management of Biotechnology from Ionis School of Technology and Management in Paris.